Clinical use of pre-emptive pharmacogenetic programmes
The clinical implementation of pharmacogenetics (the study of how genetics influence individual variations in drug response) is a key factor in the development of programmes to prevent adverse drug reactions. Yet pharmacogenetics testing in clinics is still infrequent and is mainly reactive and focused on analysing a single drug–gene interaction. Evaluation of the implementation of pharmacogenetics in the real world is necessary. Only very few pilot studies have used a pharmacogenetics panel strategy to guide drug therapy, and mostly in patients aged over 65 years in specialised care setting...
Source: thelancet.com
